硫代硫酸钠在体内、外辅佐抗癌药药效学初步研究

目的 研究硫代硫酸钠（ＳＴＳ）是否能在体内，外作为化疗药的辅药，方法：应用ＭＴＴ法研究ＳＴＳ分别与ＡＤＭ，ＭＭＣ和ＣＤＤＰ等６种抗癌单药合用时对ＢＥＬ－７４０２和ＭＧｃ８０－３细胞的细胞毒性作用，应用小鼠肝癌腹水瘤（Ｈ２２）模型判断ＳＴＳ与ＡＤＭ等３种药合用时的抗癌疗效，２０例人原发性肝癌病人肝动脉插管化疗（ＡＤＭ，ＭＭＣ和ＣＤＤＰ）前３０ｍｉｎ静脉推注ＳＴＳ（１．２５～２．５ｇ／ｍ＾２）考察ＳＴ

Preliminary pharmacodynamic study of STS as an adjuvant of the chemotherapy drugs in Vitro and in Vivo

Objective: To study whether sodium thiosulfate (STS) can be used as an adjuvant of the chemotherapy drugs. Methods: The cytotoxicity of STS combined with ADM, MMC, CDDP, 5Fu, MTX and VCR (1PPC/ml) respectively on the cells of BEL7402 and MGc803 was studied by MTT test in vitro. The ascitic hepatoma (H22) in mice were adopted to determine the anticancer effect of STS adjuvant of ADMMMC and CDDP. Being treated with STS(12525 g/m2) 30 min before drug administration,20 patients of hepatocellular carcinoma (HCC) were carried on transcatheter arterial chemoembolization with ADMMMC and CDDP to observe the adjuvant effect of STS. Results: The anticancer activity of ADM and the other agents respectively adjuvant with STS (500 g/ml) were not obviously influented (P >005), but that for CDDP was influented . It was proven that the survival time of ascitic hepatoma treated with ADM (6 mg/kg),MMC (14 mg/kg) and CDDP (45 mg/kg) alone or three drugs in addition to STS (350 mg/kg,35 mg/kg) respectively was not significantly different (P >005). The survival time of each groups was significantly longer than that of control group (P< 0001). It have also been proven that STS adjuvant of ADM, MMC and CDDP was not decreased the chemotherapry effect (RR=60%) by transcatheter arterial chemoembolization in HCC, simultaneously it alleviated the nausea and vomiting in 70%patients. Conclusion: The study provides evidence that in vivo, STS (12525 g/m2) can be used as an adjuvant of chemotherapy drugs,such as ADM,MMC, including CDDP, and so on , for decreasing nausea and vomiting effects, espacially for transcatheter chemotherapy .